Alec Stranahan
Stock Analyst at B of A Securities
(1.15)
# 1,081
Out of 4,424 analysts
19
Total ratings
58.33%
Success rate
-24.06%
Average return
Main Sectors:
Top Industries:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Upgrades: Neutral | $4 → $12 | $8.88 | +35.14% | 2 | May 10, 2024 | |
| ERAS Erasca | Downgrades: Neutral | $11 → $6 | $1.85 | +224.32% | 1 | Jan 5, 2024 | |
| RVMD Revolution Medicines | Upgrades: Buy | $34 | $37.25 | -8.72% | 2 | Jan 5, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $118 → $140 | $154.76 | -9.54% | 3 | May 25, 2023 | |
| XNCR Xencor | Initiates: Buy | $42 | $22.48 | +86.83% | 1 | May 19, 2023 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $6 → $12 | $12.28 | -2.28% | 4 | May 15, 2023 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Underperform | $34 → $9 | $16.00 | -43.75% | 2 | Apr 25, 2023 | |
| TGTX TG Therapeutics | Maintains: Underperform | $5 → $6 | $16.62 | -63.90% | 2 | Dec 29, 2022 | |
| HOOK HOOKIPA Pharma | Downgrades: Underperform | $6 → $0.5 | $0.77 | -34.90% | 1 | Dec 2, 2022 | |
| SWTX SpringWorks Therapeutics | Initiates: Buy | $45 | $40.89 | +10.05% | 1 | Dec 1, 2022 |
Novavax
May 10, 2024
Upgrades: Neutral
Price Target: $4 → $12
Current: $8.88
Upside: +35.14%
Erasca
Jan 5, 2024
Downgrades: Neutral
Price Target: $11 → $6
Current: $1.85
Upside: +224.32%
Revolution Medicines
Jan 5, 2024
Upgrades: Buy
Price Target: $34
Current: $37.25
Upside: -8.72%
Krystal Biotech
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $154.76
Upside: -9.54%
Xencor
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $22.48
Upside: +86.83%
Y-mAbs Therapeutics
May 15, 2023
Maintains: Neutral
Price Target: $6 → $12
Current: $12.28
Upside: -2.28%
Day One Biopharmaceuticals
Apr 25, 2023
Downgrades: Underperform
Price Target: $34 → $9
Current: $16.00
Upside: -43.75%
TG Therapeutics
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $16.62
Upside: -63.90%
HOOKIPA Pharma
Dec 2, 2022
Downgrades: Underperform
Price Target: $6 → $0.5
Current: $0.77
Upside: -34.90%
SpringWorks Therapeutics
Dec 1, 2022
Initiates: Buy
Price Target: $45
Current: $40.89
Upside: +10.05%